Sales, Trading & Research

Mary Stroth, Head of Equity Sales, Trading & Research, Truist Securities: Our symposium really allowed for the deepening of relationships by bringing together extremely busy people. You have the investors. You have the companies. So, coming to our conference allows people to in one day, in a short period of time, meet with as many companies and institutional investors as well as private equity and VC firms.

Brian Lian, President & CEO, Viking Therapeutics: These conferences are useful for us because we get feedback from investors that often help us understand where investor priorities are, what's most exciting to investors, and that helps us with our own internal strategic thinking around our own programs.

Marcio Souza, President & CEO, Praxis Precision Medicines: Investor interactions we had today are incredibly valuable for us. They're very diverse. There was a very large number. So by talking to a diverse group of people, several meetings, as we had today we are able to distill and to better inform everything we're doing from an incredibly important stakeholder that is our shareholders.

Kevin Koch, President and CEO, Edgewise Therapeutics: So these panel discussions are great because you get to see hear insights from other companies, and you can hear about the challenges and also the successes, and maybe you can utilize those in your own work.

Michael Allwin, Head of Healthcare Equity Capital Markets, Truist Securities: A fundamental foundation to our purpose at Truist on the biotechnology investment banking side is to identify the right investors for our corporate clients and understanding the ways to bring capital for our corporate clients from the right investors to help them unlock their strategic objectives. That's something we've tried to do with the panels, with the investor meetings over the course of the day. And, we've heard fantastic things so far.

Gregg Genova, Healthcare Sector Sales Specialist, Truist Securities: The symposium was a great way to bring both the public and private companies together to work on potential for future partnerships, future capital raising. It's critical to bring today's leaders of the biotech industry together with the innovators because they're all trying to evolve and look for the next area where to focus.

Lorenzo Paoletti, Head of Biotech Investment Banking, Truist Securities: We certainly enjoyed interacting with management teams and investors today. The conversations were incredibly productive. We have received a lot of phenomenal feedback on all the interaction.

Mary Stroth: It was so nice to see our investors and companies come together, and we look forward to seeing you all next year.